In Brief ''BRAF-like'' colorectal cancers, which are typically associated with poor patient outcome and resistance to conventional treatments, are selectively sensitive to the microtubule poison vinorelbine, suggesting that this subgroup of patients is likely to benefit from a tailored chemotherapy approach.
INTRODUCTION
Colorectal cancer (CRC) represents one of the most common cancers worldwide, with an estimated 1.2 million cases yearly and an annual mortality of over 600,000 (Jemal et al., 2011) . Due to the relatively asymptomatic progression of the disease in the early stages, patients are frequently diagnosed with metastatic disease, with a five-year survival rate of around 10% (Cidó n, 2010) . BRAF is a protein kinase downstream of RAS in the RAS-RAF-MEK-ERK kinase pathway. V600E is the most common point mutation of the BRAF gene and is present in approximately 8%-10% of the CRC patients (Tie et al., 2011; Yuan et al., 2013) . Several reports have consistently shown the negative impact of BRAF(V600E) mutation on CRC prognosis, (A) BRAF(V600E)-specific upregulated genes are used to assemble the BRAF library and perform a ''dropout'' shRNA screening. Left panel: example of a heatmap of BRAF activating a 58-gene signature across 381 colon tumor samples of one of the two datasets considered (Tian et al. 2013) . Tumors are sorted according to the signature scores. Upper row: tumors with BRAF(V600E) oncogenic mutations as measured by sequence analysis are indicated by the black boxes, and tumors without BRAF(V600E) oncogenic mutations are indicated by the white boxes. Lower row: tumors sharing the gene expression pattern of BRAF oncogenic mutation as measured by the signature are displayed as black boxes (BRAF-like subgroup), and tumors that share the gene expression pattern of BRAF-wild-type are displayed as white boxes. The BRAF-like subgroup includes tumors with V600E mutation, tumors with KRAS mutation, and tumors wild-type for KRAS and BRAF. Right panel: a schematic outline of the ''dropout'' shRNA screen for genes whose inhibition is selectively lethal in BRAF-like CC cell lines. After selecting 363 upregulated genes in BRAF(V600E) CCs tumors from the two datasets, the BRAF library was generated. regardless of the presence of the BRAF(V600E) mutation. The treatment of both early-stage and metastatic cancer patients is mainly based on chemotherapy. Predictive biomarkers of response are required to help identify the group of patients who might benefit from certain chemotherapeutic treatments and avoid unnecessary toxicity for those who will not benefit. To date, very few predictive biomarkers for chemotherapy response have been identified and none of them are used in clinical practice (Glü ck et al., 2013; Roepman et al., 2014; Sargent, 2014; Sinicrope et al., 2011; Vollebergh et al., 2014) . Functional genetic screens represent a powerful tool to identify mechanisms of drug response and synthetic lethal interactions (Berns et al., 2007; Luo et al., 2009; Prahallad et al., 2012; Steckel et al., 2012) . We applied a loss-of-function genetic screen to identify vulnerabilities of BRAF-like colon cancer cells. Here, we describe a specific Achilles heel of these cells that can be targeted by vinorelbine, a chemotherapeutic drug currently not used clinically for the treatment of colon cancer.
RESULTS

RANBP2 Suppression Is Selectively Lethal to BRAF-like Colon Cancers
To identify synthetic lethal interactions of BRAF mutant colon cancer, we performed a loss-of-function genetic screen in which we specifically focused on genes upregulated in BRAF(V600E) CCs. We hypothesized that some of these genes may be selectively required to tolerate the presence of the BRAF mutation. We identified 363 genes that are overexpressed in BRAF mutant CCs as compared to BRAF and KRAS wild-type (WT2) CCs using two gene expression datasets (Popovici et al., 2012; Tian et al., 2013) (Figure 1A , left). For each dataset, the genes overexpressed in BRAF mutant tumors were determined, using a cutoff of 0.05 on the Benjamini-Hochberg false discovery rate to control for multiple testing. We selected 163 genes common to both datasets, as well as the top 100 of the remaining upregulated genes unique to each dataset, yielding in total a set of 363 genes. The individual lists of genes are reported in Table  S1 . We then selected 1,586 short hairpin RNA (shRNA) vectors from the TRC shRNA collection (TRC-Hs1.0) to generate a sub-library targeting the 363 genes of interest (''BRAF library''). To identify those genes that are specifically lethal in BRAF(V600E) cells versus WT2 cells, we selected three CC cell lines. WiDr and Vaco432 colon cancer cell lines harbor a BRAF(V600E) gene mutation and are defined as BRAF-like by gene expression signature. The LIM1215 colon cancer cell line is wild-type for KRAS and BRAF genes (WT2) and is defined as non-BRAF-like by signature.
WiDr, Vaco432, and LIM1215 were infected with the BRAF shRNA library. The infected cells were selected for viral integration and cultured for 13 days, after which time shRNAs were recovered by PCR ( Figure 1A , right). The relative abundance of shRNA vectors was determined by next-generation sequencing of the barcode identifiers present in each shRNA vector (Table  S2) . We first considered shRNA vectors that were significantly depleted in BRAF(V600E) CC cells at day 13 as compared to day 0 by at least 50% (log2 time13/time0 % À1, p adjusted value % 0.1). Subsequently, we determined the fold depletion between BRAF mutant CC cells and LIM1215 cells and selected those shRNAs that had a ratio of more than 2-fold (WM fold change R 2). To increase the fidelity of the hits, genes represented by multiple shRNAs matching these criteria were prioritized (Table S3) . From this list we selected RANBP2 represented by three individual shRNAs for further validation and follow-up. We tested all five RANBP2 shRNAs present in the library in BRAF(V600E) cells and WT2 cells and confirmed the increased sensitivity of the BRAF(V600E) CC cells upon RANBP2 silencing as compared to WT2 CC cells (Figures S1A and S1B) . Based on their knockdown efficiency, shRNAs #1 and #3 were selected for further studies. In a second independent experiment, colony formation assays confirmed that silencing of RANBP2 with shRNA#1 and #3 specifically impaired the proliferation of the two BRAF mutant (Vaco432 and WiDr) CC cell lines, but not the WT2 CC cell line LIM1215 ( Figure 1B ). This impairment correlated with cell death as shown by increased apoptosis ( Figure 1C ).
Since the genes tested in this genetic screen are not only upregulated in BRAF mutant CCs but also in the BRAF-like CCs, we also studied RANBP2 suppression as a potential vulnerability in a larger panel of CC cell lines that are either BRAF-like or non-BRAF-like by gene signature. Cell lines were categorized as WT2, BRAF(V600E) , or KRAS mutant based on mutation status and, based on gene expression, as BRAF-like or non-BRAF like. The proliferation of none of the six non-BRAF-like CC cell lines was impaired by RANBP2 suppression, regardless of KRAS mutation status. In contrast, proliferation of all nine BRAF-like CC cell lines was dramatically inhibited upon RANBP2 suppression, regardless of KRAS and BRAF mutation status (Figures 1D and 1E) . Microsatellite instability (MSI) status did not correlate with this phenotype either. The degree of RANBP2 silencing is comparable across the different cell lines ( Figure S1C ). The sensitivity observed in BRAF-like cells is related to the silencing of the gene rather than to an unspecific effect of the hairpins since no toxicity was observed, either with scrambled RANBP2 shRNA or with pLKO as compared to parental lines ( Figure S1D ). We conclude that RANBP2 knockdown is selectively lethal for BRAF-like CC cell lines.
RANBP2 Knockdown Causes Mitotic Abnormalities in BRAF-like Cells RANBP2 is a small GTP-binding protein belonging to the RAS superfamily and, as part of the nuclear pore complex, is a crucial regulator of nucleo-cytoplasmic transport. However, it also plays an important yet ill-defined role in kinetochore function during mitosis. RANBP2 silencing has been reported to be responsible for abnormal mitotic progression and abnormal chromosome segregation, eventually leading to mitotic catastrophe (Hashizume et al., 2013; Salina et al., 2003) . We therefore asked whether RANBP2 expression in BRAF-like colon cancer cells is required for mitotic progression. We performed time-lapse microscopy experiments in three different non-BRAF-like CC cells (LIM1215, Caco2, and HCT15) and three different BRAF-like CC cells (Vaco432, WiDr, and HCT116) upon RANBP2 silencing. Cells were first transduced with GFP-tagged histone H2B (H2B-GFP) to allow visualization of the chromosomes in mitosis and then infected with RANBP2 shRNA #1 or #3 or control vector pLKO. Images were acquired every 10 min over a period of 72 hr. The degree of RANBP2 silencing is shown in Figure S2A . (Figure S2B ). These abnormalities eventually lead to death during or straight after mitosis ( Figure 2B ). In contrast only few mitotic defects (2% in LIM1215, 4% in HCT15, and 6% in Caco2, respectively) were observed in non-BRAF-like CC cells. These results show that RANBP2 suppression induced cell death in BRAF-like CC cells is driven by defects in mitosis and identifies mitosis as a potential vulnerability of BRAF-like CC cell lines.
RANBP2
Knockdown Affects Microtubule Dynamics in BRAF-like Cell Lines RANBP2 is part of the RANBP2-RANGAP1 complex. It has been shown to play a role in the interaction of kinetochores with kinetochore fibers and in regulating the function of kinetochores through its cyclophilin-like domain and E3 SUMO-ligase domain (Arnaoutov et al., 2005; Clarke, 2005) . It was hypothesized that the interaction of the RANBP2-RANGAP1 complex with kinetochores can also regulate other effectors through localized GTP hydrolysis by RAN (Clarke and Zhang, 2008) . RAN-regulated targets in mitosis include mostly microtubule-stabilizing factors and factors involved in microtubule nucleation (Clarke and Zhang, 2008) . We also observed several mitotic defects in BRAF-like CC cells upon RANBP2 suppression, including spindle defects.
To better evaluate whether any abnormalities in the microtubule (MT) nucleation could explain the essential mitotic role of RANBP2 in BRAF-like CC, we performed nocodazole washout experiments, a standard tool to study MT outgrowth from centrosomes and kinetochores. We first disassembled MTs by using high-dose nocodazole for a short time period, and after removal of the drug, the initial stage of MT regrowth at both centrosomes and kinetochores was evaluated in a time-course analysis. The first experiment was performed in a non-BRAF-like CC cell line (Caco2) and in a BRAF-like CC cell line (WiDr). Within 30 min of nocodazole removal both the non-BRAF-like CC cell line (Caco2) and the BRAF-like CC cell line (WiDr) showed an almost mature spindle, thus indicating the reversible action of the drug ( Figures 3A and 3B) . A robust microtubule growth from both centrosomes and kinetochores was observed in the non-BRAF-like CC cell line ( Figure 3A ), while a severe impairment of microtubule growth from kinetochores was observed in the BRAF-like CC cell line within the first 6 min of the time course ( Figure 3B ). To further characterize the robustness of this phenotype, we performed nocodazole washout experiments in several CC cell lines previously categorized based on the BRAF-like status. As shown in Figure 3C , we did not observe any major differences in terms of MTs outgrowth from the centrosomes between BRAF-like and non-BRAF-like CC cells within the first 6 min of the time course. However, we observed a clear impairment of microtubule outgrowth from the kinetochores in BRAF-like CC cells compared to non-BRAF-like CC cells ( Figure 3D ) in the same time frame. Sample images for the categories used to score the outgrowth from both the centrosomes and the kinetochores are reported in Figure S3A . Nucleation of MTs from kinetochores is regulated by the RAN gradient, as well by the RANGAP1-RANBP2 complex (Clarke and Zhang, 2008; Torosantucci et al., 2008) . The impairment of MTs outgrowth from the kinetochores observed in BRAF-like CC cells could explain their dependency on RANBP2. We therefore asked what the role of RANBP2 is in MTs nucleation from the kinetochores in BRAFlike and non-BRAF-like CC. Two non-BRAF-like (Caco2 and HCT15) and two BRAF-like (WiDr and HCT116) CC cell lines were infected with the RANBP2 shRNAs #1 or #3 and pLKO as a control. After puromycin selection, cells were harvested and seeded for a nocodazole washout experiment. Three independent biological replicates were performed per cell line, and the MTs outgrowth from both the centrosomes and the kinetochores was again scored within the first 6 min of nocodazole washout by using the same scoring methodology as described for Figures 3C and 3D. We considered the two cell lines in each group to belong to the same category. To increase statistical power, we combined the results of the three independent replicate measurements of the two cell lines in each group. As shown in Figure 3E , neither the MTs outgrowth from the centrosomes nor (legend continued on next page) the MT outgrowth from the kinetochores was perturbed in non-BRAF-like cell lines upon RANBP2 knockdown. Interestingly, we found that RANBP2 knockdown significantly decreased MTs outgrowth from the kinetochores in BRAF-like CC cell lines, as evidenced by the reduction of the ''weak outgrowth'' category (''+'') and the increase of the ''null outgrowth'' category (''À'').
In particular, the weak outgrowth category dropped from 61% in controls to 34% with shRNA #1 (Benjamini-Hochberg false discovery rate [FDR = 0.08]) and to 48% with shRNA #3 (FDR = 0.5). The null outgrowth category increased from 18% in the pLKO condition to 57% with hairpin #1 (FDR = 0.003) and to 41% with hairpin #3 (FDR = 0.02). The analysis for the individual cell lines with the corresponding silencing is shown in Figures S3B-S3F . These results show that silencing of RANBP2 further reduces MT nucleation from the kinetochores, suggesting that BRAF-like CC tumors rely on RANBP2 to compensate for an impairment of MTs nucleation from the kinetochores. This makes these tumors particularly vulnerable to loss of RANBP2 expression. Indeed, its loss triggers spindle perturbations that cause several mitotic defects, leading to cell death.
BRAF-like Colon Cancer Cells Are Sensitive to Vinorelbine
We found that RANBP2 loss perturbs spindle formation, prolongs the time spent in mitosis, triggers several mitotic defects, and, ultimately, induces death during or immediately after mitosis, which raises the possibility that BRAF-like CC cells are vulnerable to mitotic spindle poisons that act on microtubule dynamics. To address this, we mined the data from the Genomics of Drug Sensitivity in Cancer project (Sanger panel) to see if BRAF(V600E) CC cell lines are more sensitive to mitotic drugs as compared to WT2 CC cell lines . Data were available for a total of 15 CC cell lines that were tested for sensitivity to both vinca alkaloid compounds (vinorelbine and vinblastine) and taxanes (paclitaxel and docetaxel). As shown in Figure 4A , no significant difference in sensitivity was observed for vinblastine (Wilcoxon test p value = 0.85), paclitaxel (p value = 0.13), and docetaxel (p value = 0.2). BRAF(V600E) CC lines, however, were significantly more sensitive to vinorelbine than WT2 CC cells (p value = 0.04) with a difference of over 30-fold in the median IC 50 values. To further validate these findings we treated a panel of 22 colon cancer cell lines for 72 hr with different concentrations of vinorelbine, vinblastine, and paclitaxel. Our cell lines were previously profiled for gene expression to define their BRAF-like status and were homogeneously distributed among the two categories (11 BRAF-like and 11 non-BRAF-like cell lines). As reported in Figure 4B , we also observed a significant difference in sensitivity to vinblastine and paclitaxel in BRAF-like cells as compared to non BRAFlike cells, in contrast with what was observed in the Sanger panel. This could be explained by the relatively small number of cells tested in the Sanger panel. Despite its statistical significance, the difference observed in the median IC 50 values for paclitaxel is only about 2-fold, while for vinorelbine and vinblastine it is more than 100-fold (Table S4) .
To corroborate the sensitivity of BRAF-like CC cells to the vinca alkaloid compounds, we treated the same panel of CC cell lines with vinorelbine, vinblastine, and paclitaxel for about 2 weeks in colony formation assays. Figures 4C-4F shows that the lethal concentration of vinorelbine for non-BRAF-like CC cells ranged between 10 and >100 nM, while BRAF-like CC cells showed a lethal dose ranging between 0.01 and 1 nM. This means that BRAFlike CC cells were 10-to 10,000-fold more sensitive to vinorelbine compared to non-BRAF-like. The differences observed with paclitaxel were more limited (about 2-fold; data not shown), while vinblastine showed a difference of 10-to 100-fold ( Figures S4A  and S4B ). These results confirmed the specific vulnerability of BRAF-like CC cell lines to vinorelbine as also observed in the Sanger cell line dataset and in our short-term assays. The exquisite sensitivity of BRAF-like CC cells lines to vinorelbine was not related to an increased proliferation rate since the proliferation rate of BRAF-like CC cell lines was not significantly different from that of non-BRAF-like cell lines ( Figure S4C ). Importantly, BRAF(V600E) CC cells lines had an IC 50 for vinorelbine that was similar to that of breast and lung cancer cell lines, two solid tumors for which vinorelbine is used in clinical practice ( Figure S4D ).
To further characterize the vulnerability of BRAF-like CC to vinorelbine, H2B-YFP-expressing CC cells were analyzed by timelapse microscopy upon vinorelbine treatment (10 nM) over 72 hr. As reported in Figure 4G , while non-BRAF-like CC cells were dividing over a period of 24 hr of observation upon vinorelbine treatment, BRAF-like CC cells were mainly arrested in mitosis, with a percentage of cells dying during mitosis or slipping out of mitosis followed by cell death. After 72 hr of vinorelbine treatment, non-BRAF-like CC cells were still dividing with a minor percentage of cells dying and slipping out of mitosis, while BRAF-like CC were mainly dead with a minor percentage of cells still arrested in mitosis ( Figure 4H ). These findings were further confirmed by western blot analysis. We observed an arrest in M phase with an increase of the cyclin B1 levels after 24-48 hr of treatment and in some cases after 12 hr, followed by apoptosis in BRAF-like CC cells ( Figure S4E ), while we only observed a slight increase of cyclin B1 with mild apoptosis in HCT15 (non-BRAF-like) and a slight increase of apoptosis in LIM1215 (non-BRAF-like) over a 72-hr treatment. 
In Vivo Effects of Vinorelbine
(legend continued on next page)
Vinorelbine treatment significantly impaired tumor growth of BRAF-mutated (Vaco432) and BRAF-like (HCT116) xenografts, while no antitumor effect was observed in non-BRAF-like (SW480 and HCT15) mice (Figures 5A-5D ). While RKO cells were very sensitive to vinorelbine in vitro ( Figure 4D ) and to RANBP2 silencing ( Figure S5A ), no effect was observed in RKO xenografts ( Figure 5E ). This suggests that the drug response in vivo can be modulated by factors from the local microenvironment. In particular, TGFb can lead to powerful resistance to a number of cancer drugs, including chemotherapy (Brunen et al., 2013; Huang et al., 2012 
Response to Vinorelbine of Liver-Implanted Colon Cancer Cell Lines
The first site of metastatic dissemination of colon cancer is often the liver. Since new drugs are tested initially in the metastatic setting, we tested whether vinorelbine is active against colon cancer cells growing in the liver. We injected CC cells into the liver of NOD scid gamma mice and filmed them using intravital imaging upon vinorelbine treatment. We filmed the same imaging areas of CC liver implantation before, 24, and 48 hr post-vinorelbine/vehicle treatment with subcellular resolution through an abdominal imaging window as we described previously (Ritsma et al., 2012 (Ritsma et al., , 2013 (Figure 6A ). The CC cells expressed a chimera of H2B-tagged and photo-switchable Dendra2 (H2B-Dendra2). The visualization of chromosome condensation by the fluorescent tag was used to identify mitotic status and apoptotic bodies, and the green-to-red Dendra2 photo-marking of imaging fields was used to retrace the imaging areas in subsequent imaging sessions ( Figure 6A ) (Janssen et al., 2013) . Before treatment and during vehicle treatment ( Figure S6A) , only a few mitotic figures were observed in both the BRAF-like SNU-C5 cells and the non-BRAF-like Caco2 cells. Strikingly, when we imaged the same imaging field 24 hr after vinorelbine treatment, we observed a remarkable increase in mitotic figures and cell fragments in the BRAF-like cells implanted into the liver, but not in the non-BRAF-like cells growing in the liver ( Figure 6B ). In the next 24 hr, the number of cell fragments increased with a concomitant decrease in the number of mitotic figures (Figure 6B ). These data were fully consistent with our model that BRAF-like cells are more sensitive to vinorelbine and that the toxicity is due to a mitotic arrest followed by apoptosis. Moreover, these data suggest that liver metastases of BRAF-like colon cancers also respond to vinorelbine therapy.
BRAF(V600E) as a Predictive Biomarker of the DM4
Response in CC PDX Models DM4 is a potent cytotoxic agent derived from maytansine that blocks tubulin polymerization and interferes with the binding of vinblastine to tubulin, indicating a common mechanism of action (Prota et al., 2014) . We therefore asked whether the sensitivity of response of CC patient-derived xenograft (PDX) to DM4 would also be predicted by BRAF mutation status. Intrinsic sensitivity to DM4 of the PDX models was determined by the antitumor efficacy of a single high dose (40 mg/kg) of a non-targeting antibody (directed against human CD19, unable to bind mouse CD19) conjugated to DM4 in tumor-bearing mice (see the Supplemental Experimental Procedures). PDX sensitivity to the non-tumor-targeting antibody DM4 conjugate varied with 11/20 PDX models displaying lack of (B) Boxplot of log 10 IC 50 values for treatment of 11 BRAF-like CC cell lines (Vaco432, WiDr, HT29, RKO, SNU-C5, KM20, OXCO-1, SW1417, SKCO-1, HCT116, and LoVo) and 11 non-BRAF-like CC cell lines (LIM1215, Difi, Caco2, HCA-7, HDC54, LIM1863, HCT15, SW480, SW1116, SNU1033, and HCA-46) with vinorelbine, vinblastine, and paclitaxel. Cells were treated with vinorelbine, vinblastine, or paclitaxel for 72 hr. log 10 of IC 50 values (nM) are shown. See Table S4 . (C-F) WT2 non-BRAF-like, BRAF(V600E), KRAS mutant non-BRAF-like, and KRAS mutant BRAF-like CC cells were seeded at low confluence and treated with increasing concentrations of vinorelbine twice a week. Viability was assessed by a colony formation assay. Cells were fixed, stained, and photographed after 10 days of culture. (C) WT2 non-BRAF-like CC cells were seeded at low confluence and treated with increasing concentrations of vinorelbine twice per week. Viability was assessed by a colony formation assay. Cells were fixed, stained, and photographed after 10 days of culture. (D) BRAF(V600E) CC cells were seeded at low confluence and treated with increasing concentrations of vinorelbine twice per week. Viability was assessed by a colony formation assay. Cells were fixed, stained, and photographed after 10 days of culture. (E) KRAS mutant non-BRAF-like CC cells were seeded at low confluence and treated with increasing concentrations of vinorelbine twice per week. Viability was assessed by a colony formation assay. Cells were fixed, stained, and photographed after 10 days of culture. (F) KRAS mutant BRAF-like CC cells were seeded at low confluence and treated with increasing concentrations of vinorelbine twice a week. Viability was assessed by a colony formation assay. Cells were fixed, stained, and photographed after 10 days of culture. (G and H) Vinorelbine induces mitotic arrest followed by apoptosis in BRAF-like CC cells. H2B-YFP WT2 CC cells (LIM1215, Caco2, and HCT15) and H2B-YFP BRAF-like CC cells (WiDr, RKO, and HCT116) were treated with vinorelbine (10 nM) and filmed by time-lapse microscopy over a period of 24 hr (G) and 72hr (H). Per each CC cell lines, quantification of the main phenotypes occurring upon 24 (G) or 72 hr (H) of vinorelbine treatment is reported. A minimum of 90 cells per conditions was counted. See also Figure S4 and Table S4. sensitivity and 9/20 displaying intrinsic sensitivity (Table S5) . Examples of DM4-sensitive and DM4-resistant PDX models are shown in Figures S6B and S6C . Interestingly, the BRAFV600E-activating mutation was found exclusively in DM4-sensitive models ( Figure 6C ). Indeed, 44% of CC PDX responders carry the BRAF(V600E) mutation, while none of the non-responders carry the same BRAF-activating mutation (Fisher exact test p value = 0.026). Taken together, these data strengthen our finding of microtubules dynamic to be a specific target of BRAFV600E and eventually BRAF-like CC. ) for 2 weeks. Mean tumor volumes or weights ± SEM are shown (n = 7-9 mice per group). See also Figure S5 .
Complete Remission of a BRAF-like Colon Cancer Patient with Vinca Alkaloids A study report was published in 1994, in which 15 metastatic CC patients were treated with vinblastine in combination with bepridil to investigate if a calcium channel blocker could overcome the multi-drug resistance to vinblastine. The overall study was negative, but one out of 15 patients received complete remission that lasted over 20 years after repeated cycles of therapy with vinblastine-containing regimen (Linn et al., 1994) . We retrieved the primary tumor of the patient and performed both DNA and RNA extraction to look for mutations in KRAS, NRAS, and BRAF genes and determine BRAF-like status by gene expression profiling. The sequence data revealed that the tumor carried a KRAS mutation. Gene expression analysis revealed the tumor to be BRAF-like (Figure 6D ). This super-responder patient further supports the notion that BRAF-like CC are responsive to vinca alkaloids.
DISCUSSION
Oncogenomic studies have enabled a molecular taxonomy of colorectal cancer (Ana Sebio, 2015; Dienstmann, 2014) , but to date, this has had only a limited impact on the clinical management of this disease. BRAF(V600E) mutations occur in about 8%-10% of CRC patients and are associated with a poor prognosis, especially in the metastatic setting (Bokemeyer et al., 2011; Van Cutsem et al., 2011; Richman et al., 2009; Tol et al., 2009) . These tumors can be identified by a distinctive gene expression signature. This signature reliably identifies tumors with BRAF(V600E) mutation and a set of tumors lacking a BRAF mutation. We collectively refer to the CC tumors with this BRAF gene signature as ''BRAF-like.'' In addition to their similar gene expression profile, they are also characterized by similarly poor prognosis (Popovici et al., 2012; Tian et al., 2013) . To identify additional vulnerabilities of these tumors that can be exploited therapeutically, we used a loss-of-function genetic approach. We identified RANBP2 as an essential gene for BRAF-like CC cell lines. RANBP2 belongs to the RAS superfamily and is a major cytosolic component of filaments that derives from the cytoplasmic ring of the nuclear pore complex. More recently, RANBP2 and the RANBP2-RANGAP1 complex have been shown to play an important role in mitosis. In particular, RANBP2 has a role in the interaction of kinetochores with the microtubule bundles that extend from the centrosomes to the kinetochores (Clarke and Zhang, 2008; Joseph et al., 2004) . Depletion of RANBP2 by RNAi causes defective kinetochore structure and composition, abnormal mitotic progression, and abnormal chromosome segregation (Joseph et al., 2002; Salina et al., 2003) . In agreement with these reports, we observed several mitotic defects in BRAF-like CC cells upon RANBP2 knockdown, in particular prolonged mitosis eventually triggering cell death. The percentage of dead cells observed during the time-lapse experiment is a function of the observation time (72 hr). Hence, the colony formation assays (performed over a 10-day period) result in more significant cell death. The RAN-GTP gradient is important for the stabilization and nucleation of microtubules around kinetochores (Arnaoutov and Dasso, 2003) . RAN-GTP binds importin-b and releases factors that are involved in spindle assembly (Clarke and Zhang, 2008) , and its localization at kinetochores requires RANBP2. We found BRAF-like CC cell lines to be defective in the microtubule outgrowth from kinetochores and RANBP2 depletion to further reduce this microtubule outgrowth. We therefore hypothesize that RANBP2 allows BRAF-like CC cells to tolerate such a defect. Consequently, RANBP2 depletion results in cell death.
The specific defect of BRAF-like cells in microtubule formation unveiled a potential vulnerability of such tumors to microtubule disrupting agents. Indeed, we found that BRAF-like CC cells were 10-to 10,000-fold more sensitive to vinorelbine than non-BRAF-like CC cells. Moreover, we tested five BRAF-like and three non-BRAF-like colon cancer cells in various in vivo animal models for their sensitivity to vinorelbine. All but one cell line reacted in accordance to their gene expression profile: the BRAF-like being far more responsive than their non-BRAF-like counterparts (Figures 5 and 6) . Furthermore, in a series of 20 patient-derived xenograft (PDX) models of colon cancer, we found that BRAF(V600E) mutation is a predictive biomarker of response to DM4, a potent anti-mitotic agent with a mechanism of action similar to vinca alkaloids.
Vinorelbine has been rarely used for the treatment of colon cancer. Only three studies have been reported (Gebbia et al., 1996; Iaffaioli et al., 1995; Linn et al., 1994) . The tumor of one patient who got complete and lasting remission after vinblastine treatment could be retrieved (Linn et al., 1994) . The analysis of the sample revealed the tumor to be BRAF-like by gene expression ( Figure 6D ). While super-responders are rare, they can point at particular biomarkers that can be used to identify patient subsets likely to benefit from specific treatment. In this particular case, the identification of this patient as BRAF-like provides an incentive to test vinorelbine in this patient group, which represents some 20% of all colon cancers. However, we cannot exclude that other factors not present in our current models will modulate clinical responses to vinorelbine. A clinical study to assess the utility of vinorelbine in BRAF-like colon cancer is scheduled to start in the near future. Our data also suggest that BRAF-like CCs are attractive subtypes to target with maytansine-derived antibody drug conjugates. More generally, our findings highlight the utility of functional genetic approaches to find vulnerabilities of subgroups of cancers that can be exploited in the clinic.
EXPERIMENTAL PROCEDURES
Selection of the Genes Used for the BRAF-like shRNA Library Genes overexpressed in BRAF(V600E) tumors as compared to BRAF and KRAS wild-type (WT2) tumors from two gene expression datasets were used: Popovici et al. (2012) and Tian et al. (2013) . Genes were filtered according to variability by selecting only those features for which the difference between the 95 th and the 5 th percentiles was greater than 0.5 log2-units.
Differential expressed genes were identified with the limma package for the R statistical software (Ritchie et al., 2015) . The Benjamini-Hochberg false discovery rate (FDR) was used to control for multiple hypothesis testing, with the cutoff for statistical significance set at 0.05.
Synthetic Lethal shRNA Screen
The pooled shRNA dropout screen adapted from Prahallad et al. (2012) is described in the Supplemental Experimental Procedures.
Cell Culture and Viral Transduction Experiments were performed as described by Prahallad et al. (2012) . See the Supplemental Experimental Procedures for details.
Long-Term Proliferation Assays
For the loss-of-function assays, after puromycin selection cells were seeded into six-well plates (DiFi and SKCO See also Figure S6 and Table S5 . 
